RT Journal Article
SR Electronic
T1 Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.21.20132944
DO 10.1101/2020.06.21.20132944
A1 Maria Lucia L. Madariaga
A1 Jenna J. Guthmiller
A1 Stephen Schrantz
A1 Maud O. Jansen
A1 Chancey Christensen
A1 Madan Kumar
A1 Micah Prochaska
A1 Geoffrey Wool
A1 Amy Durkin-Celauro
A1 Won Hee Oh
A1 Laura Trockman
A1 Janani Vigneswaran
A1 Robert Keskey
A1 Dustin G. Shaw
A1 Haley Dugan
A1 Nai-Ying Zheng
A1 Mari Cobb
A1 Henry Utset
A1 Jiaolong Wang
A1 Olivia Stovicek
A1 Cindy Bethel
A1 Scott Matushek
A1 Mihai Giurcanu
A1 Kathleen G. Beavis
A1 Diego di Sabato
A1 David Meltzer
A1 Mark K. Ferguson
A1 John P. Kress
A1 Kumaran Shanmugarajah
A1 Jeffrey B. Matthews
A1 John F. Fung
A1 Patrick C. Wilson
A1 John C. Alverdy
A1 Jessica S. Donington
YR 2020
UL http://medrxiv.org/content/early/2020/06/23/2020.06.21.20132944.abstract
AB Background Convalescent plasma therapy for COVID-19 relies on the transfer of anti-viral antibody from donors to recipients via plasma transfusion. The relationship between clinical characteristics and antibody response to COVID-19 is not well defined. We investigated predictors of convalescent antibody production and quantified recipient antibody response in a convalescent plasma therapy clinical trial.Methods Multivariable analysis of clinical and serological parameters in 103 confirmed COVID-19 convalescent plasma donors 28 days or more following symptom resolution was performed. Mixed effects regression models with piecewise linear trends were used to characterize serial antibody responses in 10 convalescent plasma recipients with severe COVID-19.Findings Mean symptom duration of plasma donors was 11.9±5.9 days and 7.8% (8/103) had been hospitalized. Antibody titers ranged from 0 to 1:3,892 (anti-receptor binding domain (RBD)) and 0 to 1:3,289 (anti-spike). Multivariable analysis demonstrated that higher anti-RBD and anti-spike titer were associated with increased age, hospitalization for COVID-19, fever, and absence of myalgia (all p<0.05). Fatigue was significantly associated with anti-RBD (p=0.03) but not anti-spike antibody titer (p=0.11). In pairwise comparison among ABO blood types, AB donors had higher anti-RBD titer than O negative donors (p=0.048) and higher anti-spike titer than O negative (p=0.015) or O positive (p=0.037) donors. Eight of the ten recipients were discharged, one remains on ECMO and one died on ECMO. No toxicity was associated with plasma transfusion. After excluding two ECMO patients and adjusting for donor antibody titer, recipient anti-RBD antibody titer increased on average 31% per day during the first three days post-transfusion (p=0.01) and anti-spike antibody titer by 40.3% (p=0.02).Interpretation Advanced age, fever, absence of myalgia, fatigue, blood type and hospitalization were associated with higher convalescent antibody titer to COVID-19. Despite variability in donor titer, 80% of convalescent plasma recipients showed significant increase in antibody levels post-transfusion. A more complete understanding of the dose-response effect of plasma transfusion among COVID-19 patients is needed to determine the clinical efficacy of this therapy.Trial Registration NCT04340050Funding Department of Surgery University of Chicago, National Institute of Allergy and Infectious Diseases (NIAID) Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04340050Funding StatementDepartment of Surgery University of Chicago, National Institute of Allergy and Infectious Diseases (NIAID) Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board (IRB20-0523).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available upon request.